Mass Spectrometry of Biopharmaceuticals – improved methodologies for qualitative, quantitative and structural characterisation of drugs, proteinaceous drug targets and diagnostic molecules. (Q84230): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
(Changed label, description and/or aliases in fr: translated_label) |
||
| label / fr | label / fr | ||
Spectrométrie de masse des produits biopharmaceutiques — amélioration des méthodes de caractérisation qualitative, quantitative et structurelle des médicaments, des cibles protéinées et des molécules diagnostiques. | |||
Revision as of 16:24, 30 November 2021
Project Q84230 in Poland
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mass Spectrometry of Biopharmaceuticals – improved methodologies for qualitative, quantitative and structural characterisation of drugs, proteinaceous drug targets and diagnostic molecules. |
Project Q84230 in Poland |
Statements
3,499,706.0 zloty
0 references
3,499,706.0 zloty
0 references
100.0 percent
0 references
1 November 2017
0 references
31 October 2020
0 references
INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK
0 references
Mass Spectrometry (MS) expands into almost every area that requires qualitative and quantitative analysis of small molecules, including clinical applications. Its advantages include unsurpassed specificity, sensitivity better than most other analytical techniques, and ability to multiplex the analysis of many compounds in one analytical run. Since 2001 MS Lab IBB serves as a core MS laboratory for the community of biomedical sciences, implementing a variety of proteomic/metabolomic analyses for research groups from >70 institutions worldwide, both from academia and biopharma industry. It also provides immunosuppressive drug monitoring service for Polish transplant patients. We collaborate with numerous research groups from Poland and abroad, work out new data analysis tools and train students. Present project aims at improvements in analytical capabilities of the Lab and implementation of new procedures that will increase the scope of Lab activities or increase the results quality. (Polish)
0 references
Mass Spectrometry (MS) expands into almost every area that requires qualitative and quantitative analysis of small molecules, including clinical applications. It advantages include unsurpassed specificity, sensitivity better than most other analytical techniques, and ability to multiplex the analysis of many compounds in one analytical run. Since 2001 MS Lab IBB serves as a core MS laboratory for the community of biomedical sciences, implementing a variety of proteomic/metabolomic analyses for research groups from >70 institutions worldwide, both from academia and biopharma industry. It also provides immunosuppressive drug monitoring service for Polish transplant patients. We cooperate with numerous research groups from Poland and abroad, work out new data analysis tools and train students. Present project aims at improvements in analytical capabilities of the Lab and implementation of new procedures that will increase the scope of Lab activities or increase the results quality. (English)
14 October 2020
0 references
Identifiers
POIR.04.04.00-00-2CC8/16
0 references